A warning last week from federal regulators that the anti-diarrheal drug Imodium could cause serious heart problems will likely encourage plaintiffs to test claims in the courts, although success is far from certain, attorneys said.
In a June 7 safety announcement, the U.S. Food and Drug Administration warned that taking higher-than-recommended doses of the over-the-counter drug can lead to complications including arrhythmia, fainting and cardiac arrest. In the four decades since loperamide, the drug’s generic name, was introduced, 48 cases of serious heart problems linked to the medicine have been reported, including 10 deaths. More than half of those cases were reported since 2010, the FDA said, many of them tied to the opioid epidemic, as users have turned to the drug to self-treat withdrawal symptoms.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
